Elite Pharmaceuticals (ELTP) Stock Price, News & Analysis

Company Overview

Elite Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities. The company collaborates with contract manufacturing organizations and leverages distribution networks to supply products to wholesalers, hospitals and healthcare providers across the United States. Through these alliances, Elite Pharmaceuticals aims to streamline supply chains and enhance product availability for its key markets.

Specific information on the company’s leadership team and key historical milestones is limited in publicly available sources. Industry records indicate the management group brings experience in pharmaceutical sourcing, regulatory affairs and product development. Elite Pharmaceuticals continues to explore opportunities for organic growth, business development and potential acquisitions, positioning itself to capitalize on innovation within the specialty pharmaceutical sector.

Key Stats

• Today's Range: $0.69 to $0.71
• 50-Day Range: $0.49 to $0.73
• 52-Week Range: $0.27 to $0.82
• Volume: 1.55 million shs
• Average Volume: 2.07 million shs
• Market Capitalization: $751.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Elite Pharmaceuticals Stock Analysis - MarketRank™

Elite Pharmaceuticals scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Elite Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Elite Pharmaceuticals is -69.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elite Pharmaceuticals is -69.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Elite Pharmaceuticals has a P/B Ratio of 14.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.22% of the outstanding shares of Elite Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Elite Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elite Pharmaceuticals has recently decreased by 4.82%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elite Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Elite Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.22% of the outstanding shares of Elite Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Elite Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elite Pharmaceuticals has recently decreased by 4.82%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Elite Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for ELTP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Elite Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elite Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.42% of the stock of Elite Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.01% of the stock of Elite Pharmaceuticals is held by institutions.

ELTP Stock Analysis - Frequently Asked Questions

How have ELTP shares performed this year?

Elite Pharmaceuticals' stock was trading at $0.5411 at the beginning of the year. Since then, ELTP shares have increased by 29.3% and is now trading at $0.6999.

How were Elite Pharmaceuticals' earnings last quarter?

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) announced its quarterly earnings data on Thursday, August, 14th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $40.21 million during the quarter. Elite Pharmaceuticals had a negative trailing twelve-month return on equity of 9.88% and a negative net margin of 10.26%.
Read the conference call transcript.

How do I buy shares of Elite Pharmaceuticals?

Shares of ELTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Elite Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Elite Pharmaceuticals investors own include Research Frontiers (REFR), Co-Diagnostics (CODX), Novavax (NVAX), FuelCell Energy (FCEL), Onconova Therapeutics (ONTX), iBio (IBIO) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ELTP
• CIK: 1053369
• Web: www.elitepharma.com
• Phone: (201) 750-2646
• Fax: 201-750-2755
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.32 million
• Net Margins: -10.26%
• Pretax Margin: -1.39%
• Return on Equity: -9.88%
• Return on Assets: -4.72%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 7.23
• Quick Ratio: 5.44

Sales & Book Value

• Annual Sales: $84.04 million
• Price / Sales: 8.94
• Cash Flow: $0.02 per share
• Price / Cash Flow: 41.38
• Book Value: $0.05 per share
• Price / Book: 14.00

Miscellaneous

• Outstanding Shares: 1,073,360,000
• Free Float: 916,445,000
• Market Cap: $751.24 million
• Optionable: Not Optionable
• Beta: 0.25